Erratum

Jang, J.H., Tomiyama, Y., Miyazaki, K., Nagafuji, K., Usuki, K., Uoshima, N., Fujisaki, T., Kosugi, H., Matsumura, I., Sasaki, K., Kizaki, M., Sawa, M., Hidaka, M., Kobayashi, N., Ichikawa, S., Yonemura, Y., Enokitani, K., Matsuda, A., Ozawa, K., Mitani, K., Lee, J.W. and Nakao, S. (2021), Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Br J Haematol, 192: 190-199. https://doi.org/10.1111/bjh.17190

In the article by Jang, J.H et al. (2021), the authors have double checked the statistics of data to ensure the accuracy of results, and they found an error in the proportion of patients who were transfusion independent for both platelets and RBCs” in Table III. See below:

The last line of Table III should be corrected from "Transfusion independent for both platelets and RBCs*.....10 (83) [52–98].....9 (75) [43–95]" to "Transfusion independent for both platelets and RBCs*.....3 (25) [6–57].....6 (50) [21–79]".

2. In Table I, the first bullet point of "Erythrocyte response" should be corrected from "Increase in haemoglobin ≥90 g/l without red blood cell transfusion in patients with pre-treatment haemoglobin <90 g/l; or" to "Increase in haemoglobin ≥15 g/l without red blood cell transfusion in patients with pre-treatment haemoglobin <90 g/l; or".

The authors apologize for the error.